Bicycle Therapeutics PLC Sponsored ADR BCYC
3.69
(0.04)
(1.07%)
as of 25 Sep
- Market cap
- $199.4M
- P/E
- 0.0×
Follow BCYC
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(34.59%) | (31.21%) | (33.84%) | (32.30%) | |
| (28.47%) | (26.15%) | (28.51%) | (26.47%) | ||
ROIC |
0.00% | 0.00% | 0.00% | (64,747.54%) | |
Return on Tangible Assets |
(37.06%) | (34.65%) | (38.03%) | (35.77%) | |
Average Days of Receivables |
866.33 | 178.99 | 235.21 | 282.79 | |
Free Cash Flow per Share |
(3.49) | (3.64) | (3.32) | (2.98) | |
Free Cash Flow |
(241.87) | (252.02) | (231.69) | (208.28) | |
Capital Expenditures |
(2.14) | (2.35) | (2.46) | (2.23) | |
Piotroski F-Score |
1.00 | 2.00 | 2.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(18.92%) | (20.17%) | (20.58%) | (20.19%) | |
Accounts Receivable Turnover |
0.45 | 2.04 | 1.45 | 1.13 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.01) | 0.00 | 0.01 | 0.01 | |
Research and Development Expense of Revenue |
840.86% | 331.03% | 362.43% | 327.19% | |
Selling, General and Administrative Expense of Revenue |
282.54% | 109.34% | 119.24% | 116.41% | |
Share Based Compensation of Revenue |
134.60% | 54.37% | 57.94% | 55.16% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.96 | 1.14 | 1.05 | 1.08 | |
Depreciation/Fixed assets |
0.99 | 1.07 | 1.03 | 1.13 | |
Capex/Depreciation |
(0.32) | (0.37) | (0.42) | (0.42) | |
Revenue per Share |
0.41 | 1.05 | 0.91 | 0.88 | |
Operating CF per Share |
(3.46) | (3.60) | (3.29) | (2.95) | |
Capex per Share |
(0.03) | (0.03) | (0.04) | (0.03) | |
Capex to Sales |
0.08 | 0.03 | 0.04 | 0.04 | |
Net Profit Margin |
(884.51%) | (301.66%) | (344.95%) | (311.11%) |
Columns are period end dates